<DOC>
	<DOCNO>NCT01582503</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study evaluate efficacy safety 3 dosing regimen MEMP1972A patient allergic asthma remain inadequately control chronic therapy high dose inhale corticosteroid second controller medication.Patients randomize 4 Arms receive subcutaneous repeat dose either MEMP1972A 150 mg , 300 mg , 450 mg , placebo . Patients continue usual asthma medication throughout study . Anticipated time study treatment 36 week , 48-week follow-up .</brief_summary>
	<brief_title>A Study MEMP1972A Patients With Allergic Asthma Inadequately Controlled Inhaled Steroids And A Second Controller ( COSTA )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Adult patient , 18 75 year age inclusive Body weight &gt; /= 40 kg Physician 's diagnosis asthma least 12 month Evidence document bronchodilator reversibility define protocol Prebronchodilator FEV1 &gt; /= 40 % &lt; /= 80 % predict Visit 1 Required daily use ICS second controller minimum 3 consecutive month prior Visit 1 History least one protocoldefined asthma exacerbation 18 month prior Visit 1 Inadequately control asthma despite compliance asthma controller therapy Asthma exacerbation require systemic steroid 30 day prior Visit 1 Preexisting active lung disease asthma Any infection Clinically significant medical disease uncontrolled despite treatment likely require change therapy study unknown etiology Known immunodeficiency , include limited HIV infection , regardless treatment status Current substance abuse Former smoker &gt; 10 packyear history current smoker ; former smoker must stop smoke 12 month prior Visit 1 History anaphylaxis Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>